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Effect of Zinc Supplementation on Respiratory Tract
Infections in Children With Cystic Fibrosis
I. Abdulhamid, MD,1* F.W.J. Beck, PhD,2 S. Millard, MD,3 X. Chen, MD, PhD,1 and A. Prasad, MD, PhD2
Summary. Zinc (Zn) has significant anti-oxidant and anti-inflammatory activity. Zn deficiency can
occur in subsets of patients with cystic fibrosis (CF) especially those with malabsorption and
impaired growth. Although supplemental Zn has significantly reduced infections in various
disorders, its efficacy has not been thoroughly investigated in CF. We performed a double blind
placebo controlled pilot study to investigate the effect of daily 30mg elemental Zn for 1 year on the
rate of respiratory tract infections (RTIs), use of antibiotics andplasmacytokines in 26 childrenwith
CF (ages 7–18 years). PlasmaZn, Cu, inflammatory cytokines and ex vivo generation of IL-2were
measuredat baselineandat theendof thestudy. Thenumberof daysof oral antibioticswas lower in
Zn treated patients compared to placebo (P¼0.05). However, compared to placebo, the effect of
Zn was greater in patientswho exhibited low plasma Zn at baseline (P¼ 0.02) than those who had
plasma Zn levels identical to normal subjects (P¼ 0.55). Zn supplementation was marginally
effective in reducing percentage increase in plasma IL-6 and IL-8 while increasing the percentage
change in ex vivo generation of IL-2 in isolated mononuclear cell. In conclusion, oral intake
of 30mg/day of Zn reduced the number of days of oral antibiotics used to treat RTIs in childrenwith
CF. A higher daily Zn dose may be needed to decrease RTIs and modify immune responses.
Pediatr Pulmonol. 2008; 43:281–287.  2008 Wiley-Liss, Inc.
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INTRODUCTION
Cystic fibrosis (CF) is an autosomal recessive disease
caused by genetic mutations that code for cyclic AMP-
activated chloride channel, the CF transmembrane
regulator (CFTR).1–3 The disease affects many organ
systems, particularly the respiratory and gastrointestinal
tracts. Due to pancreatic insufficiency, malabsorption of
essential fatty acids, fat-soluble vitamins, and various
trace elements, including zinc (Zn), can occur in subjects
with CF.4,5 The airways in patients with CF are uniquely
susceptible to chronic infections with various bacterial
agents, especially Gram negative organisms such as
pseudomonas aeroginosa.6 This infection causes the
release of inflammatory cytokines, proteolytic enzymes,
and oxygen radicals which leads to bronchiectasis,
increased dead space, hypoxia, and hypercapnea.7,8
Approximately 90% of patients die of respiratory
failure as a result of chronic bacterial infections, Treat-
ment of CF lung disease is aimed at reducing airway
obstruction, treating recurrent infections, improving air-
way clearance, and maintaining optimal nutritional
status.9–11
Zn is an integral part of the structure and function of
many biological enzymes and a regulator of ion trans-
porters relevant to pulmonary function and disease in
CF and other pulmonary disorders.11–13 Zn is also known
to exhibit powerful anti-oxidant activity in several
organ systems including the lungs.11,13 For example, Zn
deficient rats developed significant lung toxicity 1 day
after exposure to high oxygen concentrations and Zn
replenishment prevented the hyperoxia lung damage in
previously Zn deficient animals.14
Zn supplementation to non-CF infants and pre-school
children resulted in reduced incidence of acute lower
respiratory infections.15 Zn supplementation lead to the
reduction of plasma concentration of inflammatory cyto-
kines, and oxidative stress markers in the absence of
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infection,16 and decreased the duration of colds in healthy
young adults.17 It also lowered the incidence of infection
and inflammatory cytokines levels in healthy elderly
subjects.18
Using plasma and red cell Zn concentrations to reflect
Zn status in CF has produced conflicting results as not all
CF patients appear to exhibit low Zn status.19 Adminis-
tration of supplemental Zn to CF patients has also been
non-conclusive for in one study, Zn therapy did not
result in improvement of clinical status, growth velocity or
pulmonary function.20 Another study showed an asso-
ciation between low Zn status and impaired IL-2 activity,
NK activity and thymulin activity in CF subjects, but there
was no investigation as whether these parameters would
be corrected following Zn supplementation.21
With these premises we initiated a pilot study to
determine whether Zn supplementation administered to
CF patients during a year long double blinded placebo
controlled trial would reduce the requirement for oral
antibiotics necessary during periods of active infection.
We also assessed whether changes in selected plasma
inflammatory cytokines and the ex vivo generation of IL-2
would be altered by oral Zn therapy. And lastly, we
investigated the hypothesis that a response to Zn
supplementation would be different in subjects with low




For this double blind placebo controlled study, a total of
26 children with CF exhibiting mild to moderate lung
disease groups A and B were recruited from the Pediatric
Pulmonary Division, Carman and Ann Adams Depart-
ment of Pediatrics, Children’s Hospital of Michigan
(CHM), and the Pediatric Pulmonary Division, DeVos
Children’s Hospital, Grand Rapids, Michigan. Subject’s
ages ranged from 7 to 18 years old. Exclusion criteria for
the study included presence of acute severe infection at
the time of enrollment, renal disease, severe hepatic
disease, gall bladder disease, sickle cell disease (SCD),
use of oral immunosuppressive drugs (steroids and non-
steroid anti-inflammatory drugs), diuretics and Zn supple-
ments. The study was approved by the Human Investi-
gative Committees in both institutions. Informed and
signed consent was obtained from parents or legal
guardians.
Study Groups
Without respect to prior Zn status, CF subjects
were randomly assigned to Group A (n¼ 13) received a
daily dose of 30 mg of elemental Zn as Zn gluconate
(15 mg/capsule) and CF subjects assigned to Group B
(n¼ 13) received placebo for 12 consecutive months.
Zn gluconate and placebo preparations were capsules
generously provided by Labcatal, Montrouge, France for
use in this study. Both groups were given identical daily
Zn-free and mineral-free multivitamin supplements for
the same period (Vitamax1 from SK Labs, Chesterfield,
MO) supplied by the CF services Pharmacy. Patients in
groups A and B were followed every 3 months and as
needed in their CF clinics for routine CF care. At each
visit, the patient’s interval medical history, height and
weight, number of hospitalizations, the use of oral
and intravenous antibiotics, pulmonary function test, and
physical examination findings were recorded.
Respiratory tract infections (RTIs) was defined when
the patient developed more than four of the following
signs or symptoms: change in sputum; new or increased
hemoptysis; increased cough; increased dyspnea;malaise,
fatigue, or lethargy; temperature above 388C; anorexia or
weight loss; sinus pain or tenderness; change in nasal
or sinus discharge; change in physical examination of the
chest; decrease in pulmonary function from a previously
recorded value; or radiographic changes indicative of
pulmonary infection.
Choice and duration of oral or parenteral antibiotics
used for treatment of RTIs were left to the discretion of the
children’s treating physicians.
Ten milliliter of heparinized whole blood was collected
at baseline and at the end of the study for determination
of plasma Zn, Cu and the inflammatory cytokines, TNF-a
IL-1b IL-6 IL-8, soluble IL-1 receptor antagonist
(sIL-1RA) and soluble TNF-a receptor 1 (sTNFR1).
Peripheral blood mononuclear cells (PBMC) were
isolated for ex vivo generation of IL-2.18,22 Sterile
procedures were carried out on all samples to ensure no
contaminants would interferewith the ELISA assays or ex
vivo generation of IL-2. Plasma samples were centrifuged
at 1,500g for 20 min at room temperature to remove
cellular components before being stored in 1ml aliquots at
208C for ELISA assays or being admixed with trace
metal free Ultrex II Nitric Acid (J.T. Baker Chemicals,
Phillipsburg, NJ) and digested for Zn and copper analysis
by flameless atomic absorption (AA).18,22
Laboratory Measurements
Aliquots of plasma samples were stored at208C until
assayed for cytokines to ensure that both pre- and post-
samples could be determined using the same high-
sensitivity ELISA kits available from R&D Systems
(Minneapolis, MN). Plasma Zn and Cu levels were
determined by flameless AA spectrophotometry with a
Zeeman background corrector (AA220Z Varian, Sugar-
land, TX).18,22
PBMCs were isolated by discontinuous density gradient
using Histopaque 1077 (Sigma–Aldrich, St. Louis, MO)
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according to the manufacturer’s protocol. Isolated PMNC
were resuspended in incubationmedia consisting of RPMI-
1640 supplemented with 10% fetal bovine serum, 1.5 gm/L
sodium bicarbonate, 0.1% gentamicin, 2 mM L-glutamine
and 50 mM b-mercaptoethanol. Cells were stimulated for
48 hr with 10 mg/ml PHA-p (Sigma, St. Louis,MO) at 378C
under an atmosphere of 85% air/5% CO2. At the termi-
nation of the experiment, supernatants were harvested and
assayed for IL-2 by ELISA (Quantikine ELISA, R&D
Systems).
Characterization of Zn Versus Znþ Subjects
Zn adequate CF subjects (Znþ) were defined as those
subjects with 90 mg/dl plasma Zn as determined by
flameless AA at baseline. Subjects exhibiting inadequate
Zn status (Zn) had plasma Zn levels 89 mg/dl or
two standard deviations below our normal database of
110 10 mg Zn/dl.18,22 Although all subjects exhibited
plasma Zn levels within the clinically accepted ‘‘normal’’
range (70–120 mg/dl),23 results from a number of our
research studies have demonstrated that subjects exhibit-
ing low Zn levels (<90 mg/dl) are more susceptible to
infections and tend to have higher levels of plasma
oxidative stress molecules and inflammatory cytokines
even in the absence of outward infections.18,22
Statistical Analyses
Baseline data comparison between Zn adequate and Zn
inadequate CF patients were determined by the Student’s
t-test. Data representing differences between pre- and
post-values were analyzed using the Student’s t-test for
plasma cytokines Zn and Cu and ex vivo generation of
IL-2, aswell as for weight, height, hemoglobin, and FEV1.
Correlation between compliance and days of oral anti-
biotic usage was determined by regression analysis using
Pearson r (GraphPad Instat Ver. 3.05 for Windows95/NT,
San Diego, CA).
RESULTS
Overall, there were no statistical differences in the
baseline parameters examined between Zn adequate and
inadequate CF children with the exception of plasma Zn
status (Table 1). Zn adequate CF patients also tended to
have higher levels of the sIL-1RA, IL-1 b, and IL-6 and
although the differences did not reach statistical signi-
ficance (Table 1).
Zn supplementation administered to 12 CF patients
(one subject dropped) resulted in a significant (P¼ 0.05)
reduction in the number of days of oral antibiotics use
per year compared to the 13 patients on placebo. However,
the response to Zn supplementation was different for
the Zn inadequate versus Zn adequate CF patients.
Average days of antibiotic use for the Zn adequate CF
subjects given Zn were not different from those given the
placebo (P¼ 0.55; Table 2). This is in contrast to the
response from the Zn inadequate CF subjects in which
the effect of Zn supplementation was significantly greater
(P¼ 0.025) compared to those given placebo (Table 2).
Compliance of Zn adequate CF subjects given Zn was
less than placebo treated Zn adequate subjects (Table 2).






Age (year) 12.0 3.4 (7–17)1 11.8 3.6 (8–18) 0.8854
Weight (kg) 37.58 13.6 (23–67) 42.67 13.0 (21–59.7) 0.3391
Height (cm) 146.53 17.12 (124–178) 147.87 14.44 (123–167) 0.8310
Hbg (g/dl) 13.66 0.85 (12.2–15.2) 13.66 0.68 (12.5–15.0) 0.9999
Pl.2 Zn (mg/dl) 101 9.8 (90–125) 82 4.9 (73–89) <0.0001
Pl. Cu (mg/dl) 106 20 (80–150) 113 20 (66–142) 0.3811
FVC-P3 83.85 12.1 (65–98) 87.0 10.8 (70–104) 0.4908
FEV1P
4 67.5 17.7 (41–100) 76.77 15.3 (54–98) 0.1660
FEF25–75 P
5 48.69 29.47 (10–109) 65.38 32.43 (12–109) 0.1829
Gen. IL-26 411 529 (25–1590) 382 695 (3–2370) 0.9058
Pl. sIL-1ra (pg/ml) 1501 1880 (149–6900) 927 938 (131–2995) 0.3384
Pl. sTNF-R1 (pg/ml) 1368 887 (348–3017) 1179 463 (716–2060) 0.5054
Pl. IL-1b (pg/ml) 2.48 2.66 (0.35–7.1) 1.47 1.08 (0.43–3.6) 0.2240
Pl. TNF-a (pg/ml) 2.84 2.13 (1.5–9.3) 2.30 1.05 (1.15–4.6) 0.4236
Pl. IL-6 (pg/ml) 6.18 5.71 (1.8–18.6) 3.82 4.99 (0.52–17.2) 0.2734
Pl. IL-8 (pg/ml) 440 864 (0–2858) 581 1427 (0–5552) 0.7639
1Values represent Mean SD (range).
2Pl. represents plasma values.
3FVC-P¼ forced vital capacity expressed as percent predicted.
4FEV1P¼ forced expiratory volume in 1 sec, expressed as a percentage of predicted.
5FEF25–75 P¼ forced expiratory flow between 75 and 25 of FVC expressed as percent predicted.
6IL-2 generated ex vivo.
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However, overall compliance of the two groups of Zn
treated subjects was similar. Moreover, Pearson correla-
tion coefficient indicated no correlation between com-
pliance and number of days of oral antibiotic usage in all
Zn supplemented subjects (r2¼ 0.025). There were no
adverse events identified for any of the subjects in this
study from oral or i.v. antibiotic use, Zn or placebo
supplementation or any other parameter associated with
this study.
Analysis of pre- versus post-values for each parameter
resulted in non-significant percent change compared to
baseline in selected parameters between the Zn supple-
mented and placebo supplemented group (Table 3). This
was more likely due to the small number of patients and
the large standard deviation within each group consisting
of both Zn inadequate and and Zn adequate CF patients. In
Zn treated CF patients, Zn supplementation was asso-
ciated with less increase in plasma IL6 and IL-8, and
a greater increase in plasma sIL-1ra and the ex vivo
generation of IL-2 (Table 3). This may indicate an anti-
inflammatory role of Zn in this group of patients.
DISCUSSION
A number of investigators have reported conflicting
relationships between Zn status and malabsorption,
impaired growth, or pulmonary function in CF
patients.5,19,21,24,25–28 Few studies found no correlation
between Zn levels and nutritional or pulmonary status19,25
Other reports found abnormal Zn status in certain patients
with CF especially those with moderate to severe growth
retardation and severe pulmonary disease.26–28 Low
plasma Zn in CF was also associated with low plasma
IL-2 levels, and an impairment of NK cell activity and low
thymulin activity.21 Thymulin activity, necessary for the
development of IL-2 producing T lymphocytes, was
dependent upon the presence of the Zn molecule being
present in the thymulin peptide structure.29 An increase in
the number of CD3þ lymphocytes positive for IL-2 after
stimulation has been reported in CF but was not correlated
with Zn status.30 In this present study, isolated PMNC
fromZn supplementedCFpatients had increased ability of
generating IL-2 over the time compared to those from
subjects administered placebo.
While some studies showed an association between Zn
deficiency, growth retardation andmalnutrition in a subset
of patients with CF, our group of CF subjects did not
appear to be ‘‘Zn deficient’’ but had plasma Zn levels still
within clinically acceptable normal range.23 Based on our
long term studies in trace metal research, we have found
that subjects with plasma levels of <90 mg/dl are more
likely to suffer adverse reactions to immunological
challenges such as cold, flu and infections than those
subjects with plasma Zn levels above this range. In this
study, Zn inadequate CF subjects exhibited lower baseline
levels of plasma sIL-1ra, sTNFR1, IL-1b, IL-6, and IL-8
than their Zn adequate counterpart. One hypothesis may
be that in CF subjects with low plasma Zn levels,
maintainence of immunological surveillance is decreased
in the absence of acute exacerbation. In CF subjects with
inadequate Zn status, Zn therapy was associated with
TABLE 2— Number of Episodes Requiring Antibiotics, Number of Days of Oral Antibiotic Usage and Compliance in Zinc
and Placebo Supplemented Subjects With Cystic Fibrosis
Parameter
Zinc adequate subjects Zinc inadequate subjects
Placebo (n¼ 7) Zinc (n¼ 5) P-value Placebo (n¼ 6) Zinc (n¼ 7) P-value
No. of episodes req. i.v. AB1 0.57 0.532 0.40 0.55 0.559 0.17 0.41 0.14 0.37 0.915
No. of episodes req. oral AB3 3.28 2.9 2.6 0.89 0.574 3.16 1.6 1.57 0.97 0.049
%Compliance4 92.8 7.6 66.7 21.1 0.012 81.4 18.8 70.3 37.7 0.566
Avg. days/year Req. oral AB5 49.1 36.6 37.4 6.0 0.55 47.5 24.3 20.5 12.8 0.025
1Average number of episodes/year requiring intravenous (i.v.) antibiotics.
2Values represent Mean S.D.
3Average number of episodes/year requiring oral antibiotics.
4Average percent compliance.
5Average days/year requiring oral antibiotic use.
TABLE 3— Percentage Increase (Decrease) in Selected







Pl2. Zn (mg/dl) 8.6 223 6.1 9.4 0.73
Pl. sIL-1ra (pg/ml) 1.9 141 11.4 101 0.84
Pl. sTNFR1 (pg/ml) 9.7 56 8.1 27 0.93
Pl. IL-1b (pg/ml) 86 304 78 188 0.94
Pl. TNF-a (pg/ml) 26 93 32 87 0.85
Pl. IL-6 (pg/ml) 173 374 106 192 0.57
Pl. IL-8 (pg/ml) 481 1507 122 337 0.41
Gen4. IL-2 (pg/ml) 55 274 185 275 0.24
1P values for difference between placebo and zinc supplemented group.
2Pl. represents plasma.
3Mean SD percent change from baseline.
4Ex vivo generation of IL-2 in PHA-p stimulated mononuclear cells.
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significantly fewer days of oral antibiotics and insigni-
ficant change in plasma inflammatory cytokines pre- to
post-therapy than their Zn adequate counterpart.However,
the small number of subjects and large SD for selected
parameters are not optimal for determination of a greater
beneficial effect for Zn inadequate subjects compared to
their Zn adequate counterpart. Changes in plasma Zn
levels, weight, height, FEV1, and Hgb in CF receiving Zn
were not different from the placebo treated CF group. This
suggests that the dose of Zn (30 mg/day) may not have
been sufficient to affect growth rate or other parameters of
lung function due to possible suboptimal absorption of Zn
from the gastrointestinal tract. Slightly higher dose of Zn
(no greater than 45 mg) may produce a more favorable
response on anthropometric, and lung function measures.
In patients with SCD in which loss of Zn due to red cell
destruction and hyperzincuria leaves approximately
70% of SCD subject with mild to moderate Zn deficiency,
supplemental Zn in dosages of 50–75mg/day are required
to reduce incidence of infection and the presence of
endogenous plasma inflammatory cytokines.31 Supple-
mental Zn at 45 mg/day has been shown to reduce the
incidence of infection and reduce plasma inflammatory
cytokines in the elderly population even in the absence of
active infection18 and to reduce the presence of oxidative
stress markers in young adults without adverse effects or
changes in copper levels.16 Various studies in developing
countries that used relatively high doses of Zn, ranging
from 88 to 150 mg per week, in pre-school children for
up to 15 months have reported significant reduction
respiratory and gastrointestinal infections with out
adverse effects.32,33
Several studies reported increased plasma and bron-
choalveolar lavage fluid (BALF) levels of various
cytokines such as IL-8 in patients with CF even in newly
diagnosed infants with and with out documented airway
infections.10,34–39 One report showed increased IL-8
in plasma and BALF and increased in sera IL-8 was
associated with age in CF subjects as compared to serum
IL-8 from normal children which decreases with age.35
Along with IL-8, increased TNF-a is also found in BALF
samples from CF subjects and similar to IL-8, is inversely
correlated to lung function FEV1.34 BALF levels of both
IL-8 and TNF-a tend to decrease with antibiotic therapy.
Compared to normal controls, other dysregulations of
immune function have been reported in CF subjects such
as decreased plasma IL-10 in response to antigenic
stimuli,40,41 increased plasma adhesionmolecules sICAM
and sE-selectin,42 and decreased IL-8 production in
isolated T cells.30 In other studies, results reflect data
obtained from CF populations separated into groups of
responders versus non-responders based on the cytokine
studied. However, rarely has the Zn status of these patients
been considered even though some subjects with CF
are known to exhibit lower plasma Zn levels. Studies
performed in non-CF adults and elderly demonstrate that
plasma levels of inflammatory cytokines and oxidative
stress markers are reduced following Zn therapy16–18,31
and provide support for Zn as an anti-inflammatory agent
in CF.
Results of our research in humans and in cell models
indicate the effect of Zn in reducing inflammatory
cytokines is at the mRNA level and involves inhibition
of NF-kB activation.43 HL-60 cells, (a promyelocytic cell
line) rendered Zn deficient and then stimulated with LPS,
produce significantly greater amounts of TNF-a, IL-1b
and IL-8 than those cells that were Zn sufficient.43
Activation of the NF-kB pathway by P. aeroginosa in
subjects with CF and in CF animal models can lead to an
overproduction of adhesion molecules, inflammatory
cytokines (IL-1b, TNF-a, IL-6, and IL-8), and oxidative
stress molecules, which in turn continue to provide
stimulus for further NF-kB activation and the relentless
vicious cycle.44,45
The most significant observation in this present
study was the association of Zn supplementation with
the reduction in the average days of oral antibiotic usage
required to treat RTIs particularly in Zn inadequate
subjects. It is possible that a more profound effect of Zn
than inflammatory cytokine reductionwas tomodulate the
airway environment. The effect of Zn on pulmonary
function also include such events as inhibition of NADPH
oxidase which generate extracellular superoxide anions11
and the restoration of chloride secretion across the CF
airway epithelia independent of changes in the CFTR as
has been demonstrated in theCFmousemodel.13 In theCF
mousemodel, direct application ofATPandZnwas shown
to trigger calcium entry via the P2X purinergic receptor
channels leading to the activation of calcium-dependent
chloride channels, circumventing the defective cyclic
AMP dependent CFTR chloride channel.13 Zn therapy
can also modulate pulmonary sodium absorption via
epithelial sodium channel (ENaC) directly and through
the regulation of redox conditions.46 The height of the
airway surface liquid lining the apical side of the
respiratory epithelium is tightly regulated and involves
a balance between sodium absorption by ENaC and
chloride secretion by the CFTR in normal children or by
activation of the calcium-dependent chloride channel in
CF with defective CFTR. Inducing ‘‘near normal’’ airway
environmental conditions by Zn in CF would provide for
suboptimal condition for infectious organisms.47
In summary, we have provided evidence that 30mg/day
supplemental Zn was associated with reduction in the
number of days of oral antibiotics used to treat RTI and
marginal reduction in the level of plasma inflammatory
cytokines in children with CF. Our study has several
limitations. The number of patients with CF was not large
enough to enhance the potential differences between the
treated groups. As a result, this study can be considered as
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a pilot study providing preliminary data for power analysis
for future studies designedwith larger number of subjects.
Slightly higher doses of Zn therapy may be needed
to statistically change anthropometric measures, lung
function, the level of plasma inflammatory cytokines, and
attenuate the severity of pulmonary exacerbations in
subjects with CF. Finally, the effectiveness of Zn therapy
may be optimally determined by assessing cytokine levels
in BALF or sputum samples which would more directly
representative of inflammation in the compartmentalized
CF airways. Further investigations are needed to under-
stand the role of Zn in mediating pulmonary infection in
CF subjects.
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